TOP NEWS

August 26, 2026
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
August 25, 2026
Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University
August 10, 2026
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
VIEW ALL

WE ARE SOCIAL